First-year real-world outcomes of faricimab in clinically significant diabetic macular oedema: a Swiss retina research network report.

ABSTRACT:

Aims

Evaluate the efficacy and safety of faricimab for treatment-naïve and pre-treated diabetic macular oedema (DME) in a real-world setting.

Methods

This multicentre, retrospective cohort study examined consecutive DME patients treated with faricimab for ≥1 year. Data were collected at predefined time points. Primary outcomes were mean changes in corrected visual acuity (VA), centre-point retinal thickness (CRT) and central subfield thickness (CST) and treatment intervals and adverse events (AEs).

Results

184 eyes with DME were included: 61 (33.2%) were treatment-naïve, and 123 (66.8%) were pretreated. In treatment-naïve eyes, VA improved from 69.7±15 Early Treatment of Diabetic Retinopathy Study letters at baseline to 73.9±14.1 after 12 months (p=0.014), while it re

SUBMITTER: Saad A 

PROVIDER: S-EPMC12863342 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature